Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Net Resources International

07:58 EST 22nd November 2017 | BioPortfolio

Here are the most relevant search results for "Net Resources International" found in our extensive news archives from over 250 global news sources.

More Information about Net Resources International on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Net Resources International for you to read. Along with our medical data and news we also list Net Resources International Clinical Trials, which are updated daily. BioPortfolio also has a large database of Net Resources International Companies for you to search.

Showing News Articles 1–25 of 578 from Net Resources International

Tuesday 21st November 2017

Varubi IV’s second-try FDA approval provides CINV patients with a new option

The treatment of chemotherapy-induced nausea and vomiting (CINV) has improved significantly over the past two decades. The current standard of...Read More... The post Varubi IV’s second-try FDA approval provides CINV patients with a new option appeared first on Drug Development Technology.

Monday 20th November 2017

Roche’s haemophilia A drug meets endpoints in Phase III trial

Roche has reported positive findings from the Phase III HAVEN 3 clinical trial of Hemlibra (emicizumab) conducted in adolescents and...Read More... The post Roche’s haemophilia A drug meets endpoints in Phase III trial appeared first on Drug Development Technology.

Umecrine begins enrolment for Phase IIa hypersomnia trial

Karolinska Development’s Umecrine Cognition has initiated patient enrolment in a Phase IIa clinical trial of its drug candidate GR3027 for...Read More... The post Umecrine begins enrolment for Phase IIa hypersomnia trial appeared first on Drug Development Technology.

Galapagos reports Phase II data of cystic fibrosis drug

Belgium-based biotechnology firm Galapagos has reported positive topline data from the Phase II ALBATROSS clinical trial of GLPG2222 in patients...Read More... The post Galapagos reports Phase II data of cystic fibrosis drug appeared first on Drug Development Technology.

The burden of multiple sclerosis is twice as high in women

Multiple sclerosis (MS) is an autoimmune disease that principally affects the central nervous system by causing nerve sheath damage and...Read More... The post The burden of multiple sclerosis is twice as high in women appeared first on Drug Development Technology.

Sunday 19th November 2017

Aerie Pharma starts Phase II trial for ophthalmic disorders

Aerie Pharmaceuticals has started dosing patients in a Phase II clinical trial being conducted to evaluate netarsudil ophthalmic solution (Rhopressa)....Read More... The post Aerie Pharma starts Phase II trial for ophthalmic disorders appeared first on Drug Development Technology.

Celldex starts Phase II trial for head and neck cancer

Celldex Therapeutics has started patient enrolment in a Phase II clinical trial of CDX-3379 to be evaluated in combination with...Read More... The post Celldex starts Phase II trial for head and neck cancer appeared first on Drug Development Technology.

US’s Seattle Children’s begins immunotherapy trial for leukaemia

Seattle Children’s hospital in the US has started a Phase I chimeric antigen receptor (CAR) T-cell immunotherapy trial (PLAT-05) in...Read More... The post US’s Seattle Children’s begins immunotherapy trial for leukaemia appeared first on Drug Development Technology.

Thursday 16th November 2017

Rafael Pharma launches Phase I pancreatic cancer trial

US-based Rafael Pharmaceuticals has launched a Phase I clinical trial of its drug candidate CPI-613 to be assessed in combination...Read More... The post Rafael Pharma launches Phase I pancreatic cancer trial appeared first on Drug Development Technology.

Sobi enrols first patient in Phase III trial for Still’s disease

Swedish Orphan Biovitrum (Sobi) has started patient enrolment in the Phase III anaSTILLs clinical trial of Kineret (anakinra) for Still’s...Read More... The post Sobi enrols first patient in Phase III trial for Still’s disease appeared first on Drug Development Technology.

M&As this week: Court Square Capital Partners, Quotient Sciences Limited, Jinzi Ham

Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors. Both Court...Read More... The post M&As this week: Court Square Capital Partners, Quotient Sciences Limited, Jinzi Ham appeared first on Drug Development Technology.

Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125...Read More... The post Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics appeared first on Drug Development Technology.

Incyte begins Phase II trial for essential thrombocythemia

Incyte has started dosing patients in a Phase II clinical trial of ruxolitinib (Jakafi) in patients with essential thrombocythemia (ET)...Read More... The post Incyte begins Phase II trial for essential thrombocythemia appeared first on Drug Development Technology.

Abilify MyCite: the first digital pill has been approved

In an effort to seek a novel business model, there has been a significant focus on pharma’s strategies to go...Read More... The post Abilify MyCite: the first digital pill has been approved appeared first on Drug Development Technology.

Japan will have the fastest growing prevalent cases of Alzheimer’s

Alzheimer’s disease (AD) is a subtype of dementia in which the brain cells die, leading to declines in memory and...Read More... The post Japan will have the fastest growing prevalent cases of Alzheimer’s appeared first on Drug Development Technology.

Wednesday 15th November 2017

Promius’s sumatriptan meets primary endpoint for migraine

Dr. Reddy’s Laboratories’ subsidiary Promius Pharma has reported positive results from the clinical trial of its ZEMBRACE SymTouch (sumatriptan injection)...Read More... The post Promius’s sumatriptan meets primary endpoint for migraine appeared first on Drug Development Technology.

TapImmune enrols last subject in Phase II breast cancer trial

US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to...Read More... The post TapImmune enrols last subject in Phase II breast cancer trial appeared first on Drug Development Technology.

Sangamo begins SB-913 dosing in Phase I/II trial for MPS II

US-based Sangamo Therapeutics has commenced Phase I/II clinical trial CHAMPIONS for its investigational candidate SB-913 in patients with mucopolysaccharidosis type...Read More... The post Sangamo begins SB-913 dosing in Phase I/II trial for MPS II appeared first on Drug Development Technology.

The future of orphan drugs in Europe

As the debate surrounding increasing healthcare costs and drug prices intensifies, the high cost of orphan drugs has emerged as...Read More... The post The future of orphan drugs in Europe appeared first on Drug Development Technology.

Innovative trial design: where regulators and payers divide

There is an increasing movement in the pharmaceutical industry away from traditional trial design as more dynamic and innovative design...Read More... The post Innovative trial design: where regulators and payers divide appeared first on Drug Development Technology.

Tuesday 14th November 2017

Seres to study microbiome therapy for immuno-oncology

Seres Therapeutics has partnered with the University of Texas’ MD Anderson Cancer Centre and Parker Institute for Cancer Immunotherapy to...Read More... The post Seres to study microbiome therapy for immuno-oncology appeared first on Drug Development Technology.

Boehringer and Lilly report positive trial data of Jardiance

Boehringer Ingelheim and Eli Lilly have reported positive data from the EMPA-REG OUTCOME trial of Jardiance (empagliflozin) in patients with...Read More... The post Boehringer and Lilly report positive trial data of Jardiance appeared first on Drug Development Technology.

Akcea launches Phase II programme for rare hyperlipidemias

US-based Ionis Pharmaceuticals’ affiliate Akcea Therapeutics has launched a Phase II clinical programme of AKCEA-ANGPTL3-L to treat rare hyperlipidemias. AKCEA-ANGPTL3-L...Read More... The post Akcea launches Phase II programme for rare hyperlipidemias appeared first on Drug Development Technology.

Monday 13th November 2017

RiboQuark starts enrolment in Phase II/III trial of QPI-1007 in China

Kunshan RiboQuark Pharmaceutical Technology has started patient enrolment in a Phase II/III clinical trial (QRK207) of ocular neuroprotectant QPI-1007 to...Read More... The post RiboQuark starts enrolment in Phase II/III trial of QPI-1007 in China appeared first on Drug Development Technology.

BeiGene starts two lymphoma trials of BGB-3111

BeiGene has started two new global pivotal clinical trials of its investigational candidate BGB-3111, a potent and selective small molecule...Read More... The post BeiGene starts two lymphoma trials of BGB-3111 appeared first on Drug Development Technology.


Quick Search
Advertisement
 

News Quicklinks